Standard
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. / the PROUD-PV Study Group.
I:
Leukemia, Bind 37, Nr. 10, 2023, s. 2129-2132.
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
the PROUD-PV Study Group 2023, '
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment',
Leukemia, bind 37, nr. 10, s. 2129-2132.
https://doi.org/10.1038/s41375-023-02008-6APA
the PROUD-PV Study Group (2023).
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Leukemia,
37(10), 2129-2132.
https://doi.org/10.1038/s41375-023-02008-6Vancouver
the PROUD-PV Study Group.
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Leukemia. 2023;37(10):2129-2132.
https://doi.org/10.1038/s41375-023-02008-6Author
the PROUD-PV Study Group. / Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. I: Leukemia. 2023 ; Bind 37, Nr. 10. s. 2129-2132.
Bibtex
@article{15bbe94bdcc74218bf20c31293d0525e,
title = "Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment",
author = "Heinz Gisslinger and Christoph Klade and Pencho Georgiev and Dorota Krochmalczyk and Liana Gercheva-Kyuchukova and Miklos Egyed and Petr Dulicek and Arpad Illes and Halyna Pylypenko and Lylia Sivcheva and Ji{\v r}{\'i} Mayer and Vera Yablokova and Kurt Krejcy and Victoria Empson and Hasselbalch, {Hans C.} and Robert Kralovics and Kiladjian, {Jean Jacques} and {the PROUD-PV Study Group}",
note = "Funding Information: This study was supported by research funding from AOP Health. Special thanks to the patients and their families, to study support staff. Statement of prior presentation: Presented in part in abstract form at Congresses of the European Hematology Association, 9–17 June 2022 and 8–11 June 2023. ",
year = "2023",
doi = "10.1038/s41375-023-02008-6",
language = "English",
volume = "37",
pages = "2129--2132",
journal = "Leukemia",
issn = "0887-6924",
publisher = "nature publishing group",
number = "10",
}
RIS
TY - JOUR
T1 - Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
AU - Gisslinger, Heinz
AU - Klade, Christoph
AU - Georgiev, Pencho
AU - Krochmalczyk, Dorota
AU - Gercheva-Kyuchukova, Liana
AU - Egyed, Miklos
AU - Dulicek, Petr
AU - Illes, Arpad
AU - Pylypenko, Halyna
AU - Sivcheva, Lylia
AU - Mayer, Jiří
AU - Yablokova, Vera
AU - Krejcy, Kurt
AU - Empson, Victoria
AU - Hasselbalch, Hans C.
AU - Kralovics, Robert
AU - Kiladjian, Jean Jacques
AU - the PROUD-PV Study Group
N1 - Funding Information:
This study was supported by research funding from AOP Health. Special thanks to the patients and their families, to study support staff. Statement of prior presentation: Presented in part in abstract form at Congresses of the European Hematology Association, 9–17 June 2022 and 8–11 June 2023.
PY - 2023
Y1 - 2023
U2 - 10.1038/s41375-023-02008-6
DO - 10.1038/s41375-023-02008-6
M3 - Comment/debate
C2 - 37634011
AN - SCOPUS:85168859320
VL - 37
SP - 2129
EP - 2132
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 10
ER -
